BG-12 (dimethyl fumarate): a review of mechanism of action, efficacy, and safety

Manufacturer's Response to Case Reports of PML

(2013) Marianne T. Sweetser et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence

(2012) G Giovannoni et al.   Multiple Sclerosis Journal

Effect of BG-12 in Subgroups of Patients with Relapsing-Remitting Multiple Sclerosis: Findings from the DEFINE Study (P01.130)

(2012) A. Bar-Or et al.   NEUROLOGY

Dimethyl Fumarate Suppresses Inflammation In Vitro Via Both Nrf2-Dependent and Nrf2-Independent Pathways (P02.108)

(2012) P. Bista et al.   NEUROLOGY

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

(2012) Robert J. Fox et al.   NEW ENGLAND JOURNAL OF MEDICINE

Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis

(2012) Ralf Gold et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Anti-Inflammatory Effects of Dimethyl Fumarate in Astrocytes Involve Glutathione and Haem Oxygenase-1

(2011) Shao Xia Lin et al.   ASN Neuro

Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway

(2011) Ralf A. Linker et al.   BRAIN

Emerging oral drugs for relapsing–remitting multiple sclerosis

(2011) Claudio Gasperini et al.   EXPERT OPINION ON EMERGING DRUGS

Fumarates improve psoriasis and multiple sclerosis by inducing type II dendritic cells

(2011) Kamran Ghoreschi et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Effect of BG-12 on contrast-enhanced lesions in patients with relapsing– remitting multiple sclerosis: subgroup analyses from the phase 2b study

(2011) Ludwig Kappos et al.   Multiple Sclerosis Journal

Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

(2011) Paul O'Connor et al.   NEW ENGLAND JOURNAL OF MEDICINE

BG-12 reduces evolution of new enhancing lesions to T1-hypointense lesions in patients with multiple sclerosis

(2010) D. G. MacManus et al.   JOURNAL OF NEUROLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fumaric Acid and its Esters: An Emerging Treatment for Multiple Sclerosis

(2009) D. Moharregh-Khiabani et al.   Current Neuropharmacology

Nuanced roles of cytokines in three major human brain disorders

(2008) Lawrence Steinman   JOURNAL OF CLINICAL INVESTIGATION

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

(2008) Ludwig Kappos et al.   LANCET

Molecular mechanisms of Nrf2-mediated antioxidant response

(2008) Wenge Li et al.   MOLECULAR CARCINOGENESIS